ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.

ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.